Reversible lesion of the corpus callosum associated with COVID-19: A case report
No Thumbnail Available
Date
2021
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may affect the central nervous system and peripheral nervous system. Major central nervous system manifestations of SARS-CoV-2 infection include seizures, meningoencephalitis, ischemic stroke, anosmia, and hypogeusia. The reversible splenial lesion syndrome was first described in 2004. Although reversible splenial lesion syndrome was initially recognized as a benign phenomenon, a second type of reversible splenial lesion syndrome was identified in later years, which has a poorer prognosis and potentially serious sequela. Reversible splenial lesion syndrome can be caused by numerous etiologies including viruses. In this report, we present a rare case of COVID-19 with reversible splenial lesion, who presented with ataxia and dizziness. © 2021, ASEAN Neurological Association. All rights reserved.
Description
Keywords
azithromycin , C reactive protein , favipiravir , hydroxychloroquine sulfate , lactate dehydrogenase , oseltamivir , adult , Article , ataxia , brain disease , case report , clinical article , computer assisted tomography , coronavirus disease 2019 , corpus callosum , dizziness , Doppler ultrasonography , electrocardiography , encephalitis , follow up , ground glass opacity , human , lumbar puncture , lung consolidation , lymphocyte count , lymphocytopenia , magnetic resonance angiography , male , middle aged , nuclear magnetic resonance imaging , polymerase chain reaction , reversible splenial lesion syndrome , risk factor